跳至主要内容
临床试验/RPCEC00000310
RPCEC00000310已完成4 期

Evaluation of the safety and efficacy of BIOMODULINA T® for the prevention of infections, including COVID-19, in older adults in Cuba. Phase IV clinical trial (COVID-19) - GEC2020BMT024

Centro Nacional de Biopreparados (BioCen)0 个研究点开始时间: 2020年5月5日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
60 years 至 none(—)
性别
All

入选标准

  • 1. Age 60 years and over.
  • 2. Any sex and skin color.
  • 3. Patients who express their consent in writing, to participate in the study and in case major cognitive impairment is present, be signed by a family member, tutor or caregiver.

排除标准

  • 1. Patients who have received treatment with BIOMODULINA T® in the previous two months.
  • 2. Patients with known hypersensitivity to any component of the formulation.
  • 3. Patients with acute allergic states or history of severe allergic reactions.
  • 4. Patients with uncontrolled breakthrough diseases including, but not limited to: acute infections with concomitant febrile illness, symptomatic congestive heart failure, unstable angina pectoris.

研究者

发起方
Centro Nacional de Biopreparados (BioCen)

相似试验